Women with AIDS face cervical cancer threat

	Tweet

According to a report issued last week by UNAIDS, access to antiretroviral therapy is beginning to reduce AIDS mortality worldwide. But Dr. Groesbeck Parham, gynecologic oncologist and Director of the Cervical Cancer Prevention Program at the Center for Infectious Disease Research in Zambia (CIDRZ) warns that women being treated for AIDS could end up dying of cervical cancer unless they have access to screening and treatment.

“We are saving women’s lives by treating them with antiretroviral therapy, but we could lose a high percentage of them to cervical cancer,” said Parham. 

Parham and his team have tested more than 10,000 Zambian women in the largest cervical cancer screening program targeting HIV-infected women in the developing world. In a study published last year in the journal Gynecologic Oncology, he reported that 90 percent of HIV-infected women presenting for antiretroviral therapy also harbor cervical cell abnormalities, conditions that left untreated can develop into cervical cancer.

“Before having access to antiretroviral medications, women living in developing nations who had AIDS typically succumbed to it before they could develop cervical cancer,” said Parham.

Currently, 80 percent of new cases of cervical cancer and 80 percent of the annual deaths occur in women who live in developing countries. Few women in poor countries have access to cervical cancer screening or treatment.

“As funds are allocated for HIV/AIDS care and treatment, we need to make sure that women’s other health issues are not swept under the carpet,” said Dr. Mulindi Mwanahamuntu, Co-Director of the CIDRZ Cervical Cancer Prevention Program.

In sub-Saharan Africa, cervical cancer is the most common female cancer and the most common cause of cancer-related death. When cervical lesions are discovered in pre-cancer stage the cure rates are high.

In the CIDRZ program, women are examined by nurses trained in a low-tech, low-cost screening protocol that allows them to identify precancerous or suspected cancer within minutes instead of waiting for results from a pap test. The women can then be treated immediately.
###

Established in 1999 as a Zambian nonprofit organization, CIDRZ is a collaboration with the University of Alabama at Birmingham. Since 2004, CIDRZ has supported the Zambian government in its provision of free, high-quality HIV care and treatment.

Contact: Dale Hanson Bourke

301-652-6515
CIDRZ Foundation

RELATED STORIES:
Scientists identify how virus triggers cervical and mouth cancer   Protein found to be the link missing between HPV infection and cervical cancer development   Health panel cautious on HPV screening vs Pap   High cervical cancer rates sign of larger problems   Post-treatment PET Scans Can Reassure Cervical Cancer Patients   HPV Vaccine Reduces Abnormal Pap Test Results   Weakened RNA Interference Reduces Survival in Ovarian Cancer   Health groups issue proposed cervical cancer screening guidelines   Cervical cancer vaccine gives long protection   Higher rates of cervical cancer amongst immigrants   Screening for cervical cancer low for immigrant women   Hysterectomy for cervical cancer feasible in obese women   Merck’s cervical cancer vaccine on sale in Europe   New cervical cancer vaccine offers women 100% protection   Singapore questions cervical cancer vaccine for teens   HPV tests better for cervical screening - experts   Newer cervical cancer test no better than the old?   HPV testing: Indications of a benefit in primary screening   Adding test for cervical cancer raises costs: study   Good results with cervical cancer vaccine in young girls   The Pill doesn’t affect cervical pre-cancer risk   UK mothers back cervical cancer vaccine for kids

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]